candisil hct 16 mg/12,5 mg tabletes
laboratorios liconsa, s.a., spain - candesartanum cilexetilum, hydrochlorothiazidum - tablete - 16 mg/12,5 mg
candisil hct 32 mg/12,5 mg tabletes
laboratorios liconsa, s.a., spain - candesartanum cilexetilum, hydrochlorothiazidum - tablete - 32 mg/12,5 mg
candisil hct 8 mg/12,5 mg tabletes
laboratorios liconsa, s.a., spain - candesartanum cilexetilum, hydrochlorothiazidum - tablete - 8 mg/12,5 mg
candisil hct 32 mg/25 mg tabletes
laboratorios liconsa, s.a., spain - candesartanum cilexetilum, hydrochlorothiazidum - tablete - 32 mg/25 mg
tertensam 1,5 mg/10 mg modificētās darbības tabletes
les laboratoires servier, france - indapamidum, amlodipinum - modificētās darbības tablete - 1,5 mg/10 mg
tertensam 1,5 mg/5 mg modificētās darbības tabletes
les laboratoires servier, france - indapamidum, amlodipinum - modificētās darbības tablete - 1,5 mg/5 mg
losartan/hydrochlorothiazide stada 50 mg/12,5 mg apvalkotās tabletes
stada arzneimittel ag, germany - losartanum kalicum, hydrochlorothiazidum - apvalkotā tablete - 50 mg/12,5 mg
losartan/hydrochlorothiazide stada 100 mg/12,5 mg apvalkotās tabletes
stada arzneimittel ag, germany - losartanum kalicum, hydrochlorothiazidum - apvalkotā tablete - 100 mg/12,5 mg
losartan/hydrochlorothiazide stada 100 mg/25 mg apvalkotās tabletes
stada arzneimittel ag, germany - losartanum kalicum, hydrochlorothiazidum - apvalkotā tablete - 100 mg/25 mg
deltyba
otsuka novel products gmbh - delamanīds - tuberkuloze, pret multidrugiem izturīga - antimikobaktērijas - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 un 5. jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.